US 12,291,752 B2
Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
Jerome Galon, Paris (FR); Franck Pages, Paris (FR); Bernard Mlecnik, Paris (FR); and Gabriela Bindea, Paris (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); UNIVERSITE DE PARIS DESCARTES, Paris (FR); and ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), Paris (FR)
Filed by INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), Paris (FR); and UNIVERSITÉ PARIS CITÉ, Paris (FR)
Filed on Dec. 27, 2021, as Appl. No. 17/562,111.
Application 17/562,111 is a continuation of application No. 14/413,856, granted, now 11,242,564, previously published as PCT/EP2013/064808, filed on Jul. 12, 2013.
Claims priority of application No. 12305836 (EP), filed on Jul. 12, 2012.
Prior Publication US 2022/0259665 A1, Aug. 18, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2537/143 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01)] 2 Claims
 
1. A method for treating a patient suffering from a lymphoma, wherein said method comprises the steps of: i) measuring in a tumor sample obtained from the patient, prior to anti-cancer treatment, the gene expression level of at least all of the following genes: CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21; ii) comparing every expression level determined at step i) with a corresponding predetermined reference value; iii) selecting the patient as being a responder to at least one immunotherapy when all expression levels determined at step i) are either higher or lower than the corresponding predetermined reference value; and iv) administering said immunotherapy to said patient assessed as being a responder thereto in step iii), wherein said at least one immunotherapy is an antibody directed against any one of CTLA4, PD1, PDL1, TIM3, LAG3, B7H3, B7H4, TREM, BTLA, LIGHT or B7H6; or an immune cell selected from T cells, NK cells, dendritic cells or B cells; or any combination thereof.